EDIT biotech catalysts & pipeline

EDITAS MEDICINE INC · Data as of 2026-09-08

Upcoming catalysts

in vivo gene editing medicines targeting HSCs — Initial data

Late 2026

We will select the lead development candidate to advance towards human proof-of-concept in September 2025 and are on track to submit an investigational new drug application by mid-2026 and achieve human proof-of-concept by year-end 2026.

Source filing

lead program — Initial data

Late 2026

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026

Source filing

EDIT-401 — Initial data

Q1 2027

EDIT-401 on track for CTN submission this month with data update in Q1 2027

Source filing

EDIT-401 — Initial data

Q3 2027

We expect to report a data update in the first quarter of 2027 and share data from at least three patients in the EDIT-401 Phase 1/2 trial by the end of the third quarter of 2027.

Source filing

Explore the free biotech catalyst calendar